HLS Therapeutics Faces Q1 Challenges, Ends Pfizer Deal

Hls Therapeutics (TSE:HLS) has released an update.

HLS Therapeutics reported a decline in their Q1 2024 financial results with revenue at $12.5 million, alongside a significant decrease in royalty revenues. Despite a 54% increase in Vascepa unit demand and a 112% rise in consistent prescribers, CEO Craig Millian announced the end of a promotional agreement with Pfizer and expressed the need for bold action to achieve profitability for Vascepa by year-end.

For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.